Status:

COMPLETED

Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer

Lead Sponsor:

National Health Research Institutes, Taiwan

Collaborating Sponsors:

Taipei Veterans General Hospital, Taiwan

Changhua Christian Hospital

Conditions:

Locally Advanced Rectal Cancer

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

This is a single arm phase II trial with combined celecoxib, tegafur-uracil, folinate and preoperative radiotherapy for patients with locally advanced rectal cancer. The primary end point is pathologi...

Detailed Description

The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer. The seco...

Eligibility Criteria

Inclusion

  • Patients with resectable or potentially resectable adenocarcinoma of the rectum.
  • Clinical stage by Magnetic Resonance Image (MRI) of pelvis, ultrasonography of liver and Chest X ray: AJCC T2 N1-2M0 or T3-4 N0-2M0 (patients who require diverting loop colostomy are eligible). Nuclear medicine study (whole body bone scan or PET scan) can be performed if clinically indicated.
  • Bi-dimensionally measurable disease by MRI, which can be done with pelvic array coil and intrarectal tube.
  • Age greater than 18 years and \< 80 years, ECOG performance status \< 2
  • Biopsy proven adenocarcinoma, superior margin of the tumor below the L5-S1 spine junction.
  • WBC \> 3.5 x109/L, neutrophil count \> 1.5x109/L, platelet count \> 100x109/L, serum bilirubin \< 1.25xULN (upper limit of normal), AST/ALT \< 3x ULN, serum creatinine \< 1.25xULN.
  • Informed consent signed.

Exclusion

  • Distant metastasis, Prior pelvic irradiation, Inflammatory bowel disease, Medical conditions which preclude radical therapy.
  • History of malignancy within five years (except nonmelanoma skin cancer, CIN cervix).
  • Pregnancy.
  • Hypersensitivity to celecoxib, NSAID, sulfonamides or 5-FU.
  • Cardiovascular disease like congestive heart failure, symptomatic coronary artery disease, or myocardiac infarction.
  • History of peptic ulcer disease or NSAID-related gastrointestinal bleeding
  • Use of aspirin, other NSAID or celecoxib in the two weeks prior to study entry.
  • Patients taking warfarin or other anticoagulating medicine.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2013

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT00931203

Start Date

July 1 2008

End Date

April 1 2013

Last Update

May 4 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mackay Memorial Hospital

Taipei, Taiwan